Eli Lilly stock rose almost 5% today, even after a choppy week, as investors focused on one central idea. The earnings story is centered on profit power. Non GAAP earnings per share of about US$8.40 came on roughly US$23.0b in quarterly revenue and a very high gross margin near 86%. That combination is what pulled sentiment sharply higher in a single session, while the longer term chart had cooled in recent weeks. The rest of the report now matters for anyone asking whether this move has gone too far or not far enough.

Love Eli Lilly's high gross margin but want a broader set of stocks with strong profitability and balance sheet support? Check out the list of solid balance sheet and fundamentals stocks (50 results)

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$22,974m vs. US$15,557.7m (up about 48%)
• Net Income, Excl. Extra Items (Q2 2026 vs Q2 2025): US$7,095m vs. US$5,660.5m (up about 25%)
• Basic EPS (Q2 2026 vs Q2 2025): US$7.94 vs. US$6.30 (up about 26%)
• Gross Margin (Q2 2026): about 86% (management highlighted this as a key profit driver for Eli Lilly)

Prefer clear visuals instead of scrolling through endless tables and dense earnings breakdowns? View Eli Lilly's valuation in an easy-to-scan chart format through the company report for Eli Lilly.

Eli Lilly Bull Case Hinges On GLP 1 Profit Engine

Bulls argue Eli Lilly can justify a premium position if its GLP 1 obesity and diabetes platform delivers scale, high margins and a broader pipeline. Q2 results hit several of those milestones. Cardiometabolic drugs Mounjaro and Zepbound contributed about US$14.9b of revenue and roughly US$6.3b of year on year growth, which matches the view that this franchise is the main profit engine. An 86.3% gross margin and raised full year revenue and non GAAP EPS guidance support the idea that manufacturing build out and mix are already showing up in profitability.

The narrative also hinges on building future pillars beyond current GLP 1s. In this area, the quarter brought concrete progress. Positive Phase 3 readouts for retatrutide, an oral launch with Foundayo gaining US access and early international approvals, plus oncology and gene editing wins, all point to multiple programs moving from story to execution.

Reveal where the surface looks calm, but the multi year models start to disagree on Eli Lilly's path. Access the full revenue, EPS and cash flow timeline in the analyst estimates for Eli Lilly.

Eli Lilly Bear Case, Strong Profit Yet Clear Weak Spots

The core bearish worry around Eli Lilly is that a concentrated GLP 1 engine faces pricing, access and execution risks that could erode the current profit profile. Q2 numbers do not show margin pressure yet, with an 86.3% gross margin and raised performance margin guidance. However, several milestones bears focus on are still unresolved. Drug pricing reform and employer pushback remain live issues. In addition, the recent Medicaid judgment and 340B disputes highlight legal and policy friction that could weigh on future economics.

Execution risk is also visible. Foundayo is trailing oral Wegovy in US prescriptions and Lilly has not yet filed it in Europe, so the franchise is not winning across every obesity segment. That supports concerns about concentration in a few metabolic products and uneven launch execution, even as the broader pipeline and heavy capacity spend are intended to reduce that dependence over time.

After recent legal disputes and questions around GLP 1 concentration, review whether Eli Lilly’s risk profile is changing faster than headlines suggest. Expose any potential blind spots with our risk analysis for Eli Lilly which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Eli Lilly's latest profit profile and GLP 1 debate have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. After you own it, use the Portfolio Command Center to cut through market noise and focus on the earnings, guidance and risk updates that actually matter to your holdings. For a longer term view, tap into crowd insight and sentiment through the Community and see how other investors are reacting to the same data. By surfacing potential catalysts and risks early, Simply Wall St helps you act with more confidence and stay ahead of the market.

Seeking Alternatives Beyond Eli Lilly?

Fresh ideas move fast. The stocks getting quiet momentum today can be the ones flying before the crowd catches on tomorrow. Scan these focused shortlists to explore opportunities early.

• Spot cash generative businesses with room to move by reviewing a curated 51 high quality undervalued stocks before the window for mispricing tightens and the market closes the gap.
• Focus on companies with AI-related revenue by filtering for 67 profitable AI stocks that aren't just burning cash while these business models are still under the radar.
• Target resilient compounding potential and steadier cash flows by zeroing in on 79 resilient stocks with low risk scores before defensive quality becomes more widely recognized in valuations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.